In this issue of Neuron, Royal et al. (2018) find that a mutant form of the TRESK ion channel linked to migraine undergoes alternative translation to produce an inhibitory protein that blocks TREK channels, leading to neuronal hyperexcitability and migraine in rodents.
Imagine that normal lighting or certain odors would make your jaw clench in discomfort, triggering the appearance of flashing lights, zig-zags, or blind spots across your visual field, only to be followed by nausea and an intolerable headache. Whether or not you can relate to this experience, 10%-15% of the population is all too familiar with these debilitating sensations, collectively known as migraine with aura. Unfortunately, for some individuals, migraines simply run in the family. While this may be disheartening news for those with a family history, human geneticists have studied heritable forms of migraine to identify the underlying causative mutations and uncover potential new targets for treatment.
Human genetics approaches have led to landmark studies pinpointing causative mutations for a variety of disorders, ranging from craniofacial anomalies (Dixon et al., 2011) to chronic pain (Dib-Hajj et al., 2007) . Generally, linkage analysis of affected individuals (i.e., from genomewide association studies) and/or analysis of whole exomes (from next-generation sequencing) are used to identify mutations underlying a heritable trait or disease. In the case of migraine with aura, it was discovered that certain individuals carry a frameshift mutation resulting in a truncated version of the two-pore potassium channel (K2P) gene TRESK, called ''TRESK-MT.'' All individuals carrying TRESK-MT suffer from an inherited form of migraine with aura (Lafreniè re et al., 2010) . TRESK potassium channels, along with other related K2P channels such as TREK, regulate the excitability of a variety of neurons, including somatosensory neurons that transduce painful stimuli (Kang and Kim, 2006) . Human geneticists hypothesized that loss of TRESK function would increase somatosensory neuronal excitability, particularly in the trigeminal ganglia (TG) neurons innervating the face and head, to trigger migraines in individuals with the mutation. Mutant TRESK-mediated hyperexcitability could explain the allodynia, or pain in response to normally innocuous stimuli, experienced by migraineurs both during and in between migraine episodes.
While identifying mutations is key to understanding the inciting factors in a disease, such studies are not designed to answer why a particular mutation is causative. Typically, we assume that many mutations simply ''break'' the gene-a so-called loss of function-or result in a protein product that inhibits the function of wild-type protein-known as a dominant-negative mutation. Since TRESK proteins were thought to form functional homodimers, the dominant-negative inheritance pattern of TRESK-MT was attributed to mutant TRESK proteins impeding the function of wild-type TRESK, thereby promoting hyperexcitability. If migraines are simply caused by a loss of TRESK function, then any ''gene-breaking'' mutation should lead to migraine. But two findings challenged this straightforward model and left scientists at a loss for how TRESK-MT could cause migraine. First, another dominantnegative mutation in TRESK, the point mutant TRESK-C110R, reduces TRESK currents in sensory neurons but does not trigger sensory neuron hyperexcitability (Guo et al., 2014) . Second, and most surprisingly, the TRESK-C110R mutation is not associated with human migraine (Andres-Enguix et al., 2012). How, then, does the frameshift TRESK-MT mutation, but not TRESK-C110R, cause migraine?
In this issue of Neuron, Royal et al. solved this mystery by showing that TRESK-MT promotes hyperexcitability by impeding the function of TREK potassium channels that regulate sensory neuron excitability. The frameshift in TRESK-MT enables alternative translation of TRESK mRNA; that is, a new protein product is made from a different translational start site within the TRESK mRNA. In the case of TRESK, alternative translation produces a dominant-negative truncated protein (TRESK-MT1) along with a newly described protein product (TRESK-MT2) translated from a start site created by the frameshift. TRESK-MT increases TG neuron excitability primarily because TRESK-MT2 inhibits TREK potassium currents, not because of loss of TRESK function ( Figure 1 ). The TRESK-C110R point mutant, in contrast, does not affect TREK and merely blocks TRESK function. The authors have dubbed their newly discovered phenomenon ''frameshift mutationinduced alternative translation initiation'' (fsATI). fsATI represents a novel mode by which frameshift mutations can alter a gene's function, and opens the field to new ways of thinking about the genetics of disease.
Royal et al. initially asked whether the behavior of TRESK, and therefore TRESK-MT, might be more complex than previously thought. They proposed that one possible explanation for the behavior of the TRESK mutants could be due to interactions between TRESK and other K2P channels. Despite the sequence dissimilarity of K2Ps, they are known for interacting to form functional heterodimers. However, it was unclear how TRESK interacts with other K2Ps. Using a single-molecule immunoprecipitation assay (called SiMPull; see Jain et al., 2012) , they found that TRESK physically interacts with TREK-1 and TREK-2, which are expressed within the same subsets of somatosensory neurons. As previously shown, overexpression of TRESK-MT or TRESK-C110R inhibits whole-cell TRESK currents (Andres-Enguix et al., 2012). However, unlike previous studies, they found that TRESK-MT, but not TRESK-C110R, inhibits TREK-1/2 currents in heterologous cells and TG sensory neurons. Moreover, they showed that TRESK-C110R fails to interact with TREK-1 and -2. Electrophysiology of sensory neurons confirmed that TRESK-MT increases neuronal excitability primarily via inhibition of TREK and not TRESK currents, whereas TRESK-C110R does not affect TREK currents or excitability.
The authors then hypothesized that TREK-1 and TREK-2, not yet implicated in migraine, may underlie allodynia and increased neuronal excitability observed in a mouse model of migraine. Indeed, they found that TREK-1/2 doubleknockout mice display baseline tactile allodynia similar to wild-type mice in the migraine model, suggesting that loss of TREK-1/2 activity promotes a constitutive migraine-like phenotype. TRESK-MT overexpression in TREK-1/2 knockouts has no effect on either increased TG neuronal excitability or allodynia. In support of the model that TRESK-MT triggers migraine via modulation of TREK-1/2 activity, allodynia in TREK-1/2 knockouts is attenuated by a migraine drug.
How does TRESK-MT alter TREK-1/2 function? The simplest explanation was that TRESK-MT physically interacts with TREK-1 and TREK-2 to inhibit their function, but the authors hit a snag when they discovered that the N-terminal-tagged TRESK-MT did not pull down either TREK channel. However, careful analysis of the mutant TRESK gene showed that TRESK-MT contains additional translation start sites within its coding region not found in wild-type TRESK, suggesting it may encode for more than one protein. In eukaryotic cells, mRNA transcripts can undergo ''alternative translation initiation'' (ATI) wherein a single mRNA can encode multiple protein products due to presence of multiple translational start sites. Indeed, the authors discovered that immunoprecipitation using either an N-or C-terminal-tagged wild-type TRESK could pull down TREK-1/2. However, only the C-terminal-tagged TRESK-MT could pull down TREK-1/2, and tagging both ends of TRESK-MT with different fluorescent proteins results in pull-down of two separate TRESK protein products: TRESK-MT1 and TRESK-MT2. Of these, only MT2 interacts with TREK-1/2. By overexpressing MT1 and MT2 separately in TG neurons, they found that MT2, but not MT1, increases the excitability of neurons in a TREK-1/2-dependent manner. Moreover, viral mis-expression of just MT2 in rat somatosensory neurons induces hyperexcitability and tactile allodynia, similar to that observed in the TREK-1/2 knockout mice and a mouse model of migraine. Taken together, these results implicate MT2 in migraine-associated allodynia, and explain how different phenotypes might arise from varying TRESK mutations that promote loss of channel function.
Intriguingly, the authors mined a human exome database and discovered another frameshift TRESK mutation associated with migraine. Introduction of this other mutant TRESK gene into heterologous cells also produced both MT1 and MT2 proteins and inhibited TREK-1/2 currents, suggesting that alternative translation of TRESK may be a common mechanism underlying migraine susceptibility in humans. Thus, TREK channels or TRESK-MT2/TREK interactions might be attractive targets for future migraine therapies, especially in those individuals carrying fsATI TRESK mutations. Furthermore, the TRESK-TREK subpopulation of somatosensory neurons includes peptidergic nociceptors that, upon excitation, release calcitonin gene-related peptide (CGRP) and other inflammatory mediators that promote hyperexcitability and vasodilation, and are directly implicated in migraine. Indeed, currently available migraine therapies target downstream consequences of activation of these nociceptors. For example, a CGRP receptorblocking antibody (erenumab) was recently approved for use in migraine. Likewise, vasoconstricting 5HT1 agonists like sumatriptan have long been mainstay migraine drugs. In addition, topiramate, a widely used migraine medication, reduces neural activity, but is a non-selective drug that targets many different classes of ion channels and receptors and as such has undesirable side effects. Selective blockade of nociceptors via inhibition of TRESK-TREK or TREK channels may represent a more effective and selective treatment for migraine.
Royal et al. show a key role for TRESK fsATI in migraine-associated allodynia, which is just one facet of this debilitating and widespread disorder. It will be interesting to see whether inhibition of TREK-1/2 contributes to other aspects of migraine, such as aura or hypersensitivity to light, sound, and smell. Likewise, TRESK and TREK channels are expressed in many subtypes of neurons in the peripheral and central nervous system. The consequences of TRESK fsATI in these other cell types should be examined.
In light of recent advances in wholeexome sequencing and the advent of human phenotypic databases, it will be interesting to examine whether humans harboring TREK mutations also experience migraine susceptibility, consistent with the proposed model. Moreover, given that fsATI underlies at least one inherited form of migraine, it will be fascinating to see if fsATI could explain the complex etiology of other neurological disorders. Already there are studies suggesting that alternative translation may play a role in other heritable diseases (Scheper et al., 2007) . For example, some members of a family carrying retinoblastoma (RB)causing mutations failed to develop tumors, in part because alternative translation of their RB1 gene resulted in protein products that actually suppressed tumor formation (Sá nchez-Sá nchez et al., 2007) . The question then arises of whether other disorders have a nuanced pathophysiology rooted in alternative translation. Future work examining the role of fsATI in other inherited neurological disorders will no doubt be of great interest.
